ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions
View by Date

Sunday, November 5, 2017

9:00AM-11:00AM
Abstract Number: 60
Low and Moderate Intensity Exercise Suppresses Inflammatory Responses in an Acute Mouse Model of Gout and Suggests Therapeutic Efficacy
Biology and Pathology of Bone and Joint Poster I
9:00AM-11:00AM
Abstract Number: 582
Low Dose Computed Tomography Detects More Progression of Bone Formation in Comparison to Conventional Radiography in Patients with Ankylosing Spondylitis
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I
9:00AM-11:00AM
Abstract Number: 20
Low Molecular Weight BAFF Receptor Antagonists Restrain Infiltration of B Cells into Organs of Autoimmune Model Mice By Suppressing B Cell Activation
B Cell Biology and Targets in Autoimmune Disease Poster
9:00AM-11:00AM
Abstract Number: 500
Low Patient Global Assessment Scores in Rheumatoid Arthritis Are Associated with Pain and Physical Function in Patients Treated with Tofacitinib: A Post-Hoc Analysis of Phase 3 Trials
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules
9:00AM-11:00AM
Abstract Number: 600
Low Rates of Major Adverse Cardiac Events, Malignancies, and Serious Infections in Subjects with Psoriasis and Psoriatic Arthritis Treated with Apremilast for ≥156 Weeks: Pooled Analysis from the Esteem and Palace 1-3 Phase 3 Trials
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I
9:00AM-11:00AM
Abstract Number: 665
Low Vitamin D Is Associated with End Stage Renal Disease in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes
9:00AM-11:00AM
Abstract Number: 664
Low Vitamin D Is Associated with Thrombosis in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes
9:00AM-11:00AM
Abstract Number: 188
Lupus Low Disease Activity State Is Associated with Reduced Direct Medical Costs in Patients with Systemic Lupus Erythematosus
Health Services Research Poster I
9:00AM-11:00AM
Abstract Number: 719
Lupus Nephritis in Isolation or Accompanied By Extra-Renal Manifestations: Early Lessons from the Accelerating Medicines Partnership
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes
9:00AM-11:00AM
Abstract Number: 762
M10, a Caspase Cleavage Product of the Hepatocyte Growth Factor Receptor, Downregulates Bone Morphogenetic Protein-9-Induced Smad1/5/8 Phosphorylation and Collagen Production in Human Lung Fibroblasts
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I
9:00AM-11:00AM
Abstract Number: 420
Machine Learning in Rheumatology: Development and Validation of a Predictive Model for Rheumatoid Arthritis Mortality Using Random Survival Forests
Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response
9:00AM-11:00AM
Abstract Number: 54
Maintaining Angiogenesis Prevents Glucocorticoid Induced Osteonecrosis
Biology and Pathology of Bone and Joint Poster I
9:00AM-11:00AM
Abstract Number: 146
Major Cardiovascular Events Among an Inception Cohort of Seniors with Rheumatoid Arthritis
Epidemiology and Public Health Poster I: Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 406
Mapping Changes in Monocyte and Macrophage Populations in the Synovium: An Aging Study in Arthritic KRN Ag7 Mice
Rheumatoid Arthritis – Animal Models Poster I
9:00AM-11:00AM
Abstract Number: 789
Markers of Inflammation and Patient-Reported Measures As Predictors of Relapse in Giant Cell Arteritis
Vasculitis Poster I: Large Vessel Vasculitis
  • «Previous Page
  • 1
  • …
  • 29
  • 30
  • 31
  • 32
  • 33
  • …
  • 64
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology